The global statistics are terrifying. Prostate cancer is the fourth most common cancer in all populations, the second most common cancer among men worldwide, and ranks first in Europe, where a third ...

Add Yahoo as a preferred source to see more of our stories on Google. New research has found 'wide variation' in the use of prostate cancer testing across the UK. (Getty Images) (Korrawin via Getty ...

Former President Joe Biden received his last known blood test to check for prostate cancer in 2014, a spokesperson said Tuesday — two days after Biden revealed he has an aggressive form of prostate ...

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...

Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers breaking ...

READ MORE: Scandal of NHS prostate cancer postcode lottery: Thousands of men at greater risk of death as 96 trusts fail to meet target to start treatment, forcing hundreds to wait months for care A ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...

The prostate health index (PHI) is a blood test that more accurately assesses the risk of prostate cancer than a traditional PSA test. The PHI combines three different PSA tests to create one risk ...

Wolinsky is a Chicago-based medical journalist and publisher of The Active Surveillor, a Substack newsletter that covers lower-risk prostate cancer and active surveillance. In 2002, at age 55, I ...

It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.

Former Premier League goalkeeper Shaka Hislop says it is "alarming" that tests for prostate cancer are not "regular and "standardised" in the United Kingdom. The 56-year-old was diagnosed with the ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data from a phase 3 trial of the multi-center, randomized ...